WallStSmart
DCPH

Deciphera Pharmaceuticals LLC

NASDAQ: DCPH · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

$25.59
+0.00% today

Updated 2026-06-05

Market cap
$2.21B
P/E ratio
P/S ratio
12.65x
EPS (TTM)
$-2.21
Dividend yield
52W range
$0 – $0
Volume
0.0M

Deciphera Pharmaceuticals LLC (DCPH) Financial statements

SEC filings — annual and quarterly data.

Profit margin
-119.34%
Operating margin
-129.14%
ROE
-60.25%
ROA
-26.60%
Debt/equity
0.08x

Margin trends — annual

Gross margin Operating margin Profit margin
YearRevenueNet incomeGross marginOp. marginProfit margin
2015$0.00$-19.82M
2016$0.00$-25.94M
2017$0.00$-50.28M
2018$0.00$-99.85M
2019$25.00M$-191.49M96.68%-802.90%-765.97%
2020$42.09M$-266.49M99.47%-644.36%-633.19%
2021$96.15M$-296.84M96.95%-312.10%-308.73%
2022$134.04M$-178.93M93.46%-136.32%-133.49%
2023$163.36M$-194.94M97.72%-129.14%-119.34%

Frequently asked questions

What is Deciphera Pharmaceuticals LLC's revenue?

Deciphera Pharmaceuticals LLC's trailing twelve-month revenue is $174.91M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is DCPH?

In its most recent fiscal year, DCPH ran a gross margin of 97.72%, an operating margin of -129.14%, and a net margin of -119.34%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does DCPH generate?

DCPH produced $-147.47M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is DCPH's balance sheet healthy?

DCPH holds $83.51M in cash and equivalents against — in long-term debt, on $350.92M of shareholder equity. That debt is best read against the cash flow the business throws off each year.